Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
[Fam]-trastuzumab deruxtecan achieved a tumor response of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
AstraZeneca and Daiichi Sankyo’s [fam]-trastuzumab deruxtecan demonstrated an impressive 14.8-month median duration of response and 16.4-month median progression-free survival
CALQUENCE significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukemia
Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24 months
Trial also showed 87% of patients on CALQUENCE alone remained free of disease progression or death at 24 months
IMFINZI® (durvalumab) granted FDA priority review for the treatment of patients with extensive-stage small cell lung cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for IMFINZI in combination with standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2020.
CALQUENCE approved in the US for adult patients with chronic lymphocytic leukemia
Two Phase III CALQUENCE trials demonstrated superior progression-free survival across multiple settings while maintaining favorable tolerability
CALQUENCE combined with obinutuzumab and as monotherapy reduced the risk of disease progression or death by 90% and 80%, respectively in ELEVATE-TN
Latest AZ&You Blog Articles
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.